a Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA). The Chi-square test was used for statistical analysis and a *p*-value of less than 0.05 was regarded as statistically significant. Full informed consent was obtained from all patients prior to examination of the specimens.

Results

Clinicopathological features of the patients are shown in Table I. Twenty-two patients received paclitaxel 180 mg/m^2 + carboplatin AUC (area under the concentration curve) = 6 every three weeks, eight patients received docetaxel 70 mg/m^2 + cisplatin (CDDP) 60 mg/m^2 every three weeks, and six patients received cyclophosphamide 750 mg/m^2 + CDDP 75 mg/m^2 every three weeks as postoperative chemotherapy. Secondary cytoreductive surgery was performed with a final outcome scored as a partial response (PR), no change (NC), or progressive disease (PD) based on the World Health Organization criteria (1979) by assessment using magnetic resonance imaging every four weeks.

A total of 64 samples from 32 (88.9%) cases produced usable results for *hMLH1* MET. In these cases, no primary tumor exhibited *hMLH1* MET while 18 (56.3%) of the secondary tumors, resected after treatment with Pt-chemo, showed a change from unmethylated *hMLH1* promoter to *hMLH1* MET. Table II shows the microsatellite status and *hMLH1* protein expression in the *hMLH1* MET secondary tumors. No *hMLH1* MET tumor showed expression of *hMLH1* protein, and 11 out of 16 cases where microsatellite status was determined (68.8%) were defined as MSI-H (high frequency of microsatellite instability) tumors. These results suggest that a change in *hMLH1* MET after Pt-chemo in EOC correlates with both loss of *hMLH1* protein expression and microsatellite instability.

Table III shows the correlation between clinicopathological factors and *hMLH1* MET status. The frequency of *hMLH1* MET was significantly greater in cases with a PR to platinum-based chemotherapy than in cases with NC or PD, while no significant differences were found by histological subtype (serous or non-serous), type of platinum agent used (CDDP: cisplatin, or CBDCA: carboplatin), or whether taxanes (paclitaxel and docetaxel) were combined with the Pt-chemo or not. In addition, no *hMLH1* MET was found in secondary tumors after fewer than 4 courses of treatment, while 64.3% of tumors treated with 4 or more courses of Pt-chemo exhibited *hMLH1* MET (p=0.059). These results suggest that *hMLH1* MET occurred after about three courses of Pt-chemo, and that the responsiveness of tumors during Pt-chemo was associated with the development of *hMLH1* MET. Therefore, *hMLH1* MET would not be a cause of intrinsic resistance but a major molecular cause of acquired resistance to Pt-chemo in EOC.

Table I. *Clinicopathological features of the patients.*

Total number of cases	36
Mean age (range)	54.2±8.3 years (21-68)
Histological subtype	
Serous	28
Mucinous	4
Endometrioid	5
Clear-cell	2
Regimens of chemotherapy	
Paclitaxel + CBDCA	22
Docetaxel + CDDP	8
Cyclophosphamide + CDDP	6
Mean treatment courses (range)	5.7±1.6 (1-13)
Direct effects of chemotherapy	
Partial response	19
No change	10
Progressive disease	7
Mean treatment dose of platinum agents (range)	
CDDP (mg)	417.9±90.9 (320-630)
CBDCA (mg)	3543.5±956.4 (1820-6231)

CDDP, cisplatin; CBDCA, carboplatin; therapeutic effect was graded by WHO criteria.

Discussion

Since DNA mismatch repair (MMR)-deficient cell lines exhibit resistance to alkylating agents (6-10), many studies have been conducted to determine correlations between the function of the MMR system and resistance to anticancer agents, especially CDDP resistance. Brown *et al.* (8) reported that the proportion of negative expression of *hMLH1* increased in samples taken after chemotherapy compared to untreated tumors while no significant difference was observed for *hMSH2*, *hMSH6*, or *hPMS2*. Furthermore, Fink *et al.* (9) reported that lack of *hMSH2* activity was also a cause of CDDP resistance. Aebi *et al.* (10) compared characteristics of resistance to CDDP among *hMLH1*, *hMSH2* deleted or mutated MMR-deficient cell lines and MMR-proficient clones by complementation of each gene by chromosome transfer, and reported that loss of either *hMLH1* or *hMSH2* contributed significantly to resistance to CDDP. Therefore, it is generally agreed that loss of DNA mismatch repair genes is a cause of CDDP resistance. However, although these studies have revealed correlations between MMR deficiency and intrinsic resistance to platinum agents, it is still unknown whether MMR deficiency is also correlated with acquired resistance to platinum agents.

Previously, we have reported that MSI in ovarian cancer tissues changed during Pt-chemo, and that the loss of *hMLH1* protein expression affected this transformation to MSI (5). However, it was still unknown when and why MSI changes during Pt-chemo. Since studies on colorectal cancer (11, 12)

Table II. *Microsatellite status and hMLH1 protein expression of cases with hMLH1 promoter methylation.*

Case no.	Histologic subtypes	Regimen of chemotherapy	No. of treatment courses	Direct effects	Microsatellite status	Expression of *hMLH1* protein
1	Serous	CP	4	NC	MSI-H	Negative
2	Serous	DP	4	NC	MSI-L	Negative
3	Serous	TC	4	PR	MSI-H	Negative
4	Serous	TC	4	PR	MSS	Negative
5	Clear	DP	5	PR	MSI-L	Negative
6	Endometrioid	TC	5	PR	MSI-H	Negative
7	Serous	TC	5	PR	MSI-H	Negative
8	Serous	TC	5	PR	MSI-L	Negative
9	Endometrioid	CP	6	NC	MSI-H	Negative
10	Serous	DP	6	PR	MSI-H	Negative
11	Serous	DP	6	PR	NA	Negative
12	Serous	TC	6	PR	MSI-H	Negative
13	Serous	TC	6	PR	MSI-L	Negative
14	Serous	TC	6	PR	MSI-H	Negative
15	Serous	TC	6	PR	MSI-H	Negative
16	Serous	CP	7	PR	NA	Negative
17	Serous	TC	7	PR	MSI-H	Negative
18	Serous	TC	13	PR	MSI-H	Negative

CP, Cyclophosphamide + Cisplatin; DP, Docetaxel + Cisplatin; TC, Paclitaxel + Carboplatin; PR, partial response; NC, no change; MSS, microsatellite stable tumor; MSI-L, low frequency of microsatellite instability; MSI-H, high frequency of microsatellite instability; NA, not amplified.

revealed that hypermethylation occurred frequently in the *hMLH1* promoter, the clinical role of *hMLH1* MET has been studied in several types of cancer. However, the reported influence on survival of loss of *hMLH1* has also been found to be variable: a poor prognostic factor in esophageal cancer (13), but a good prognostic factor in colorectal (14) and gastric cancer (15). Although the correlation between *hMLH1* MET of the primary tumor and patient survival is still unknown, several studies (16, 17) have clearly demonstrated that *hMLH1* expression is reduced by treatment with anticancer agents. Gifford *et al.* (18) studied *hMLH1* MET in plasma DNA after carboplatin/taxoid chemotherapy of patients with EOC who were enrolled in the SCOTROC clinical trial, and reported that acquisition of *hMLH1* MET plasma DNA at relapse predicted poor overall survival. Furthermore, Nadin *et al.* (19) studied DNA damage and *hMLH1* and *hMSH2* protein expression in peripheral blood lymphocytes after chemotherapy and reported that examination of expression of *hMLH1* in peripheral blood lymphocytes is useful in predicting the response to chemotherapy. We have demonstrated that the status of tumor microsatellite regions was changed from stable to unstable by Pt-chemo (5), and in the present study have clarified that *hMLH1* MET is also changed by Pt-chemo and that *hMLH1* MET is the main cause of change of MSI in secondary tumors after Pt-chemo. Furthermore, the present results also show that *hMLH1* MET occurred more frequently in tumors after four or more courses of Pt-chemo than after fewer courses, and *hMLH1* MET was more frequently observed in partially responsive tumors than in tumors with

Table III. *Correlation between clinicopathological factors and hMLH1 methylation in informative cases.*

Factor (n)	Methylated (%)	Unmethylated (%)	*p*-value
Histological subtype			
Serous (23)	15 (65.2)	8 (34.8)	
Non-Serous (9)	3 (33.3)	6 (66.7)	$p=0.102$
Regimen of chemotherapy			
CDDP-based (12)	7 (58.3)	5 (41.7)	
CBDCA-based (20)	11 (55.0)	9 (45.0)	$p=0.853$
Taxanes non-combined (5)	3 (60.0)	2 (40.0)	
Taxanes combined (27)	15 (55.6)	12 (44.4)	$p=0.759$
Direct effects of chemotherapy			
PR (16)	15 (93.8)	1 (6.2)	
NC or PD (16)	3 (18.8)	13 (81.2)	$p<0.001$
Treatment courses			
3 courses ≥ (4)	0 (0.0)	4 (100.0)	
4 courses ≤ (28)	18 (64.3)	10 (35.7)	$p=0.059$

CDDP, cisplatin; CBDCA, carboplatin; Taxanes, paclitaxel or docetaxel; PR, partial response; NC, no change; PD, progressive disease. Direct effects were determined according to the WHO criteria.

NC or PD outcomes, indicating that the presence of *hMLH1* MET was correlated with acquired resistance to Pt-chemo while another mechanism, such as mutation of *p53*, was responsible for intrinsic resistance to Pt-chemo. Therefore, if several of the partially responsive tumors had a change in the *hMLH1* promotor from unmethylated to methylated during Pt-chemo, this would explain the lack of complete response and

the reason for the patient remaining in the PR category. Although why the *hMLH1* promoter is methylated by Pt-chemo is still unknown, we suspect that *hMLH1* MET during Pt-chemo is a temporary change which protects cancer cells from undergoing apoptosis due to exposure to DNA-toxic agents because sensitivity to platinum agents returns after a 6- to 12-month treatment interval from platinum agents (20).

According to the present results, treatment with demethylating agents brings the possibility of improving the effects of Pt-chemo and the prognosis of advanced EOC. Moreover, our *in vitro* study demonstrated that the DNA polymerase reaction inhibitors Ara-C and gemcitabine showed greater efficacy in MMR-deficient cell lines than in MMR-proficient cell lines (21). Large-scale clinical trials using demethylating agents or DNA polymerase reaction inhibitors with evaluation of the *hMLH1* MET status of tumors will be needed to improve the long-term prognosis of advanced EOC.

References

1 du Bois A, Lueck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nits U, Jackisch C, Emons G, Wagner U, Kuhn W and Pfisterer J: A randomized clinical trial of cisplatin/paclitaxel *versus* carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst *9*: 1320-1329, 2003.

2 McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Eng J Med *334*: 1-6, 1996.

3 Leith CP, Kopeckey KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR and William CL: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood *94*: 1086-1099, 1999.

4 Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M and Miyazaki K: Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett *192*: 227-235, 2003.

5 Watanabe Y, Koi M, Hemmi H, Hoshiai H and Noda K: A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer *85*: 1064-1069, 2001.

6 Koi M, Umar A, Chauhann DP, Cherian SP, Carethers JM, Kunkel TA and Boland CR: Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine tolerance in colon tumor cells with homozygous *hMLH1* mutation. Cancer Res *54*: 4308-4312, 1994.

7 Watanabe Y, Haugen-Strano A, Umar A, Yamada K, Hemmi H, Kikuchi Y, Takano S, Shibata Y, Barrett JC, Kunkel TA and Koi M: Complementation of an *hMSH2* defect in human colorectal carcinoma cells by human chromosome 2 transfer. Mol Carcinog *29*: 37-49, 2000.

8 Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG and Anthoney DA: hMLH1 expression and cellular response of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene *15*: 45-52, 1997.

9 Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL and Howell SB: *In vitro* and *in vivo* resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res *57*: 1841-1845, 1998.

10 Aebi S, Kurdi-Haider B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB: Loss of DNA mismatch repair in aquired resistance to cisplatin. Cancer Res *56*: 3087-3090, 1996.

11 Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM and Kolodner R: Methylation of the *hMLH1* promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res *57*: 808-811, 1997.

12 Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA and Baylin SB: Incidence and functional cosequence of *hMLH1* promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA *95*: 6870-6875, 1998.

13 Uehara H, Miyamoto M, Kato K, Cho Y, Kurokawa T, Murakami S, Fukunaga A, Ebihara Y, Kaneko H, Hashimoto H, Murakami Y, Schichinohe T, Kawarada Y, Itoh T, Okushiba S, Kondo S and Katoh H: Deficiency of hMLH1 and hMSH2 expression is poor prognostic factor in esophageal squamous cell carcinoma. J Surg Oncol *92*: 109-115, 2005.

14 Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L and Cavazzini L: Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and stage III colorectal cancer patients. J Clin Oncol *24*: 2359-2367, 2006.

15 Endoh Y, Tamura G, Ajioka Y, Watanabe H and Motoyama T: Frequent hypermethylation of the *hMLH1* gene promoter in differential-type tumours of the stomach with gastric foveolar phenotype. Am J Pathol *157*: 717-722, 2000.

16 Kishi K, Doki Y, Yano M, Yasuda T, Fujiwara Y, Takiguchi S, Kim S, Higuchi I and Monden M: Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. Clin Cancer Res *9*: 4368-4375, 2003.

17 Mackay HJ, Cameron D, Rahilly M, Paul J, Kaye SB and Brown R: Reduced MLH1 expression in breast tumors after chemotherapy predicts disease-free survival. J Clin Oncol *18*: 87-93, 2000.

18 Gifford G, Paul J, Vasey PA, Kaye SB and Brown R: The acquisition of *hMLH1* methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res *10*: 4420-4426, 2004.

19 Nadin SB, Vargas-Roig LM, Drago G, Ibarra J and Ciocca DR: DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy. Cancer Lett *239*: 84-97, 2006.

20 Harries M and Gore M: Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncology *3*: 537-545, 2002.

21 Takahashi T, Min Z, Uchida I, Arita M, Watanabe Y, Koi M and Hemmi H: Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors. Cancer Lett *220*: 85-93, 2005.

Received December 20, 2006
Revised March 16, 2007
Accepted March 21, 2007

EUROPEAN JOURNAL OF CANCER 43 (2007) 1452–1459

available at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejconline.com



Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer

Kohkichi Hata[a,*], *Dipok Kumar Dhar*[b], *Yoh Watanabe*[c], *Hidekatsu Nakai*[c], *Hiroshi Hoshiai*[c]

[a]*Department of Tumor Biology, Kagawa Prefectural University of Health Sciences, Takamastu 761-0123, Japan*
[b]*Institute of Hepatology, RF & UCL Medical School, London WC1E 6HX, UK*
[c]*Department of Obstetrics and Gynecology, Kinki University of Medicine, Osaka-Sayama 589-8511, Japan*

ARTICLE INFO

Article history:
Received 21 December 2006
Received in revised form
16 February 2007
Accepted 7 March 2007
Available online 17 April 2007

Keywords:
Metastin
AXOR12
Gene expression
Real-time quantitative RT-PCR
In situ hybridisation
Epithelial ovarian cancer
Prognosis

ABSTRACT

Background: Metastin, a product of the KiSS-1 gene, is a ligand for a G-protein-coupled receptor (AXOR12) and is a strong suppressant of metastasis. The aim of this study was to evaluate whether *metastin* and *AXOR12* gene expressions affect prognosis of patients with epithelial ovarian cancer.

Methods: The expression levels of *metastin*, AXOR12 and *glyceraldehyde-3-phosphate dehydrogenase (GAPDH)* gene expression were analysed by the real-time quantitative reverse transcription-polymerase chain reaction in 76 epithelial ovarian cancer surgical specimens. Their expression (metastin/GAPDH and AXOR12/GAPDH ratios) was correlated with the clinical findings. Furthermore, cellular distribution of metastin and AXOR12 mRNA was examined by *in situ* hybridisation on tissue sections.

Results: The median and range of mRNA expression for metastin and AXOR12 were 0.047 and 0.01–13.57, and 4.00 and 0.011–135.13, respectively. Patients were dichotomised into two groups having low and high expressions by using the median value as the cutoff. A good agreement was noticed between *metastin* and *AXOR12* gene expression levels (kappa coefficient; 0.74). The presence of residual tumour following resection was negatively associated with *metastin* ($P = 0.0084$) and *AXOR12* ($P = 0.0148$) gene expressions indicating an association of low expression of these genes in more aggressive, and advanced tumours. By univariate Cox regression analysis, the prognosis of the patients with low *AXOR12* gene expression was significantly worse than those with high *AXOR12* gene expression ($P = 0.030$). The combination of *metastin* and *AXOR12* gene expression level was also significantly associated with the prognosis ($P = 0.049$). Transcripts for both metastin and AXOR12 were detected in the epithelial ovarian carcinoma cells.

Conclusions: These results present a new insight into the understanding of the biological behaviour of epithelial ovarian cancer. Metastin/AXOR12 signalling may suppress the invasive phenotype of epithelial ovarian cancer.

1. Introduction

KiSS-1 is a human metastasis suppressor gene,[1] which suppresses metastasis of human melanoma[2] and breast carcinoma[3] without affecting tumourigenicity. Ohtaki and colleagues[4] showed that Kiss-1 encodes a carboxy-terminally amidated peptide with 54 amino-acid residues, which have been isolated from human placenta as the endogenous ligand

* *Corresponding author:* Tel.: +81 87 870 1578; fax: +81 87 870 1204.
E-mail address: hata@chs.pref.kagawa.jp (K. Hata).
0959-8049/$ - see front matter © 2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejca.2007.03.004

of a G-protein-coupled receptor (named AXOR12 or hOT7T175) and is named as metastin. The binding of metastin to its receptor inhibits chemotaxis *in vitro*, enhances the expression and activity of focal adhesion kinase and inhibits the ability of meatstin receptor overexpressing melanoma cells to metastasise *in vivo*.[4] In another model, metastin inhibited chemotaxis, invasion, motility and growth of Chinese hamster ovary (CHO) cells designed to overexpress the metastin receptor, and attenuated pulmonary metastasis of hOT7T175-transfected B16–BL6 melanomas.[5]

Recently, a significant reduction in KiSS-1 or metastin expression has been reported in tumours with high metastatic potential.[6–10] Moreover, reduced KiSS-1 expression became a strong prognostic marker in patients with urinary bladder cancer[9] and gastric carcinoma.[10] These findings may open the possibility of future clinical application of these proteins, KiSS-1, metastin, and AXOR12, for prevention of cancer invasion and metastasis, and thus may improve patient prognosis. These promising results provoked us to evaluate the expression of these genes and their prognostic impact on epithelial ovarian cancer, which is the fourth most common cause of cancer death in women and the most common cause of death in women dying from a gynaecologic tumour.[11]

In this study, we sought to determine mRNA expression of metastin and AXOR12 using the real-time quantitative reverse transcription-polymerase chain reaction (RT- PCR) in cases of epithelial ovarian cancer. The gene expression of metastin and AXOR12 was correlated with clinicopathological parameters and their impact on patient survival was evaluated. Moreover, cellular distribution of metastin and AXOR12 mRNA was examined by *in situ* hybridisation.

2. Patients and methods

2.1. Patients

Patients with epithelial ovarian cancer treated between January 1990 and December 2005 at the Kinki University Hospital, Osaka-Sayama, Japan, were included in this study. Eligible patients had a histological diagnosis of primary epithelial ovarian cancer, and were suitable for adequate surgical staging. Patients were excluded from this study when surgically resected specimens were not available, had undergone any kind of preoperative therapy, had cancers other than ovarian cancer or had severe complications. All research was conducted with patients' informed consent to have their tissue banked for future unspecified studies. The present study conformed with the ethical standards of the Helsinki declaration of World Medical Association. The median age of the 76 eligible patients was 56 years (range, 31–84 years). Twenty-one of them were premenopausal. Patients were staged according to the 1987 criteria recommended by FIGO.[12] There were 34 stage I patients, 3 stage II patients, 35 stage III patients and 4 stage IV patients. The staging system defined by FIGO, as described elsewhere[13,14], assumes that an adequate staging operation has been performed. Tumours were classified histologically according to the World Health Organization (WHO) criteria[15] as serous ($n = 39$), mucinous ($n = 18$), endometrioid ($n = 10$), clear cell ($n = 8$) and transitional cell ($n = 1$). The tumours were classified histologically as either having well differentiated ($n = 46$) or being moderately differentiated ($n = 14$), or poorly differentiated ($n = 7$).[16] The number of poorly differentiated tumours is smaller than that of well differentiated tumours. This seems to be unusual compared to European series. However, this is a typical population in Japanese ovarian cancers.[13,14,17]

The surveillance for recurrent disease usually consisted of physical examination, Papanicolaou smear and serology with tumour marker examination (e.g. CA 125, CA 19-9, carcinoembryonic antigen, sialyl Tn) every month for the first year, every 2 months for the second and third years, and every 3 months for the fourth and fifth years. After 5 years, the patients were examined semiannually. A chest radiograph and CT scan or sonogram were obtained every 6 months for 5 years after surgery and every year thereafter, and if necessary MRI was performed. Recurrent disease was confirmed either pathologically or radiographically or serologically. Follow-up information was obtained from medical record, letter or telephone contact with patients, and information from referring physician. Survival data were available for all patients (median follow-up 36.5 months, range 4–196 months). Of these, 73 patients received platinum and/or paclitaxel-based chemotherapy. Two patients with stage Ia tumours of endometrioid adenocarcinoma and mucinous cystadenocarcinoma, and one with stage IV tumour of serous cystadenocarcinoma had no further treatment after surgery.

2.2. Tissue specimen and RNA preparation

Fresh surgical specimens from all patients were obtained. A dissecting microscope was used to avoid any contamination of cancerous tissue with non-cancerous tissue material. The tissue samples were stored at −80 °C for subsequent quantification of mRNA expression.

2.3. RNA preparation and real-time quantitative RT-PCR procedure

Total RNA was isolated from frozen tissues using a commercially available extraction method (Isogen; Nippon Gene Inc., Tokyo, Japan).

Complementary DNA (cDNA) was prepared by random priming from 1000 ng of total RNA using a First-Strand cDNA Synthesis kit (Pharmacia-LKB, Uppsala, Sweden). We performed real-time quantitative PCR using the TaqMan system (Applied Biosystems). The expression levels of each gene (*metastin* and *AXOR12*) and internal reference glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) were measured by multiplex PCR using TaqMan probes labelled with 6-carboxyfluorescein (FAM) or VIC, respectively. The primers and TaqMan probes were designed using Primer Express v 2.0 software (Applied Biosystems). The sequences of each primer and TaqMan probe (forward primer, reverse primer, TaqMan probe) were *metastin*, 5′-GCAGGTCCTTCTCCCGCT-3′, 5′-GCCAGATCCCCGCACC-3′, 5′-CACCAGCACCGCGCCCTG-3′; *AXOR12*, 5′-TGGCACCCACGCAGCTA-3′, 5′- AGTTGCTGTAGGACATGCAGTGA-3′, 5′-CCGCCTACGCGCTTAAGACCTGG-3′. We purchased the Pre-Developed TaqMan Assay Reagents, GAPDH primer/probe set from Applied Biosystems. Real-time PCR

amplification and product detection was performed using an ABI PRISM 7300 Sequence Detection System (Applied Biosystems) as recommended by the manufacturer. The simultaneous measurement of each gene-FAM and GAPDH-VIC permitted normalisation of the amount of cDNA added per sample. The quantity of cDNA for each experimental gene was normalised to the quantity of GAPDH cDNA in each sample. Relative expression was determined by using the ΔΔCt (threshold cycle) method according to the manufacturer's protocol (User Bulletin #2). Each assay included a standard curve sample in duplicate, a no-template control and a cDNA sample from the tumour specimen in triplicate. All samples with a coefficient of variance higher than 10% were retested. Furthermore, the sequences of PCR products were analysed and they were identical to the sequence of each gene.

2.4. *In situ hybridisation*

To localise metastin and AXOR12 mRNA, *in situ* hybridisation technique was employed. Parraffin-embedded sections were used for *in situ* hybridisation. Serial sections were used from each patient for sense and antisense probe. A digoxigenin-labelled sense and antisense RNA probe was transcribed by T3 and T7 RNA polymerase, respectively, with a DIG RNA labelling kit according to the manufacturer's instructions (Boehringer Mannheim, Mannheim, Germany). Hybridisation and the immunohistochemical steps were done as we described previously.[10,18] Placental tissue served as a positive control.

2.5. *Statistical analysis*

Kappa statistic was used as a measure of agreement between *metastin* and *AXOR12* gene expression. The kappa coefficient values of up to 0.40 were considered to indicate poor agreement; values between 0.41 and 0.75, moderate to good agreement; and values greater than 0.75, excellent agreement.[19] Mann–Whitney *U* test and Kruskal–Wallis one-way analysis of variance by ranks were used as appropriate for the evaluation of differences between end-points. The Cox proportional hazards model was used in survival analysis. Maximum likelihood parameter estimates and likelihood ratio statistics (LRS) in the Cox proportional hazards models were obtained with the use of a statistical package, EPICURE.[20] Kaplan–Meier curves were compared by the univariate Cox regression analysis. All *P* values presented were two-sided. A *P* value of less than 0.05 was considered significant.

3. Results

3.1. *Each gene expression and clinicopathological features*

The median and range of mRNA expression were 0.047 and 0.01–13.57, and 4.00 and 0.011–135.13 for metastin and AXOR12, respectively. The patients were divided into low or



Fig. 1A – *Metastin* gene expression in patients with negative and positive residual disease.

Table 1 – Clinicopathological features and gene expression

Clinicopathological features	Metastin gene expression median (range)	*P*-value	*AXOR12* gene expression median (range)	*P*-value
Age at the time of diagnosis		0.0058		0.1069
<56 (*n* = 36)	0.119 (0.001–5.689)		5.683 (0.054–32.309)	
>56 (*n* = 40)	0.021 (0.001–13.566)		3.205 (0.011–36.116)	
FIGO stage		0.0539		0.1279
I–II (*n* = 37)	0.071 (0.001–13.566)		4.529 (0.133–33.588)	
III–IV (*n* = 39)	0.021 (0.001–5.689)		3.056 (0.011–36.116)	
Residual disease		0.0084		0.0148
Negative (*n* = 43)	0.097 (0.001–13.566)		4.853 (0.133–36.116)	
Positive (*n* = 33)	0.010 (0.001–5.689)		2.560 (0.011–25.007)	
Histological subtype		0.0832		0.071
Serous (*n* = 39)	0.014 (0.001–3.424)		1.651 (0.033–36.116)	
Mucinous (*n* = 18)	0.160 (0.001–5.689)		5.585 (0.011–23.375)	
Endometrioid (*n* = 10)	0.073 (0.001–3.256)		10.341 (0.054–33.588)	
Clear cell (*n* = 8)	0.139 (0.003–13.566)		11.413 (0.133–23.869)	
Histological grade		0.2289		0.1575
Well differentiated (*n* = 46)	0.054 (0.001–5.689)		4.258 (0.011–33.588)	
Moderately differentiated (*n* = 14)	0.009 (0.001–1.963)		3.414 (0.033–36.116)	
Poorly differentiated (*n* = 7)	0.003 (0.001–0.049)		1.856 (0.054–4.441)	
Unclassified (*n* = 9)	0.133 (0.003–13.566)		6.838 (0.133–23.869)	



Fig. 1B – A G-protein-coupled receptor (AXOR12) gene expression in patients with negative and positive residual disease.



Fig. 1C – *Metastin* gene expression according to the age at diagnosis (<56 versus ⩾56).

high groups for *metastin* and AXOR12 gene expressions using the median value as the cutoff, respectively. A good agreement was noted between *metastin* and AXOR12 gene expression levels (kappa coefficient; 0.74). The values of *metastatin* and AXOR12 gene expressions in ovarian cancers are classified according to patients' age at diagnosis, stage of disease, presence or absence of residual tumour mass after initial surgery, histological subtype and grade (Table 1). The presence of residual tumour was negatively associated with *metastin* (P = 0.0084) (Fig. 1A) and AXOR12 (P = 0.0148) (Fig. 1B) gene expressions, respectively. The patients' age at diagnosis was significantly associated with *metastin* gene expression (P = 0.0058) (Fig. 1C).



Fig. 2A – Comparison of survivals between groups with a high G-protein-coupled receptor (AXOR12) gene expression and low AXOR12 gene expression according to univariate Cox regression analysis.



Fig. 2B – Comparison of survivals between groups with both low *metastin* and a G-protein-coupled receptor (AXOR12) gene expression, and others according to univariate Cox regression analysis.

3.2. *Each gene expression and prognosis*

As shown in Fig. 2A, we found the prognosis of the patients with low AXOR12 gene expression to be significantly worse than that of those with high AXOR12 gene expression by univariate Cox regression analysis (P = 0.030). *Metastin* gene



Fig. 2C – Comparison of survivals between groups with both high *metastin* and *a G-protein-coupled receptor (AXOR12)* gene expression, and others according to univariate Cox regression analysis.

Table 3 – The results of multivariate Cox regression analysis

Variables	Hazard ratio	95% confidence interval	P-value
FIGO stage			
I–II (*n* = 37)	Referent		
III–IV (*n* = 39)	12.08	2.39–61.16	0.003
Histological grade			
Others (*n* = 69)	Referent		
Poorly (*n* = 7)	3.08	1.13–8.41	0.028
AXOR12 gene expression ratio			
High (*n* = 38)	Referent		
Low (*n* = 38)	0.35	0.03–4.92	0.439
Combination of metastin and AXOR12 gene expression ratio			
Others (*n* = 43)	Referent		
Both low (*n* = 33)	1.44	0.27–7.64	0.668
Both high (*n* = 33)	Referent		
Others (*n* = 43)	5.26	0.50–55.21	0.167

expression itself had no impact on patient survival, however, combination of *metastin* and AXOR12 gene expression had significant impact on patient prognosis (Figs. 2B and 2C). Moreover, FIGO stage (stages III–IV; $P = 0.001$), residual disease (positive; $P = 0.0004$) and histological grade (poorly; $P = 0.0005$) were found to be significantly associated with a poor prognosis in univariate Cox regression analysis (Table 2). Older age at the time of diagnosis and serous tumours type are generally thought to be more aggressive.[21] However, no significant association for these variables could be found in this study (Table 2). Multivariate Cox regression analysis revealed that FIGO stage (III–IV; $P = 0.003$) and histological grade (poorly; $P = 0.028$) are the independent prognostic factors in this series (Table 3).

3.3. *In situ* hybridisation

Transcripts for *metastin* and *AXOR12* were detected in the syncytiotrophoblasts of placental tissue as positive controls, respectively (Fig. 3). Transcripts for *metastin* and *AXOR12* were

Table 2 – The results of univariate Cox regression analysis

Variables	Hazard ratio	95% Confidence interval	P-value
Age at the time of diagnosis value	1.02	0.98–1.06	0.244
FIGO stage			
I–II (*n* = 37)	Referent		
III–IV (*n* = 39)	11.50	2.64–50.01	0.001
Residual disease			
Negative (*n* = 43)	Referent		
Positive (*n* = 33)	14.34	3.31–62.14	0.0004
Histological subtype			
Others (*n* = 37)	Referent		
Serous (*n* = 39)	1.10	0.45–2.69	0.838
Histological grade			
Others (*n* = 69)	Referent		
Poorly (*n* = 7)	5.29	2.07–13.49	0.0005
Metastin gene expression ratio			
High (*n* = 38)	Referent		
Low (*n* = 38)	2.32	0.89–6.05	0.084
AXOR12 gene expression ratio			
High (*n* = 38)	Referent		
Low (*n* = 38)	3.06	1.11–8.43	0.030
Combination of metastin and AXOR12 gene expression level			
Others (*n* = 43)	Referent		
Both low (*n* = 33)	2.52	1.004–6.33	0.049
Both high (*n* = 33)	Referent		
Others (*n* = 43)	3.00	1.004–8.99	0.049



Fig. 3 – *In situ* hybridisation analysis of metastin and a G-protein-coupled receptor (AXOR12) expression in a section of the placenta. Metastin (A, original ×400) and AXOR12 (C, original ×400) mRNA-expressing cells are found in the syncytiotrophoblasts, respectively. In metastin (B, original ×400) and AXOR12 (D, original ×400) sense-control hybridisation, only background colour with no distinction is observed, respectively.

observed in the epithelial ovarian carcinoma cells, respectively (Fig. 4).

4. Discussion

The predicted KiSS-1 proteins consist of 145 amino acids, with a secretory signal sequence located at the N-terminus, suggesting that KiSS-1 functions as a secretory protein.[22] However, the full-length KiSS-1 protein has not been detected in a secreted form. Instead, three truncated fragments of KiSS-1 occur naturally in human placenta and are termed as metastin (54 amino acids), kisspeptin-14 (14 amino acids) and kisspeptin-13 (13 amino acids).[4] Furthermore, metastin was identified as a ligand for an orphan G-protein-coupled receptor, designated as AXOR12.[23] Jiang and colleagues[24] reported the differential expression of KiSS-1 and AXOR12 in human ovarian cancer cell lines. SKOV3 cells expressed AXOR12, but lacked the expression of KiSS-1. They established KiSS-1 infected SKOV3 cell line, and found that KiSS-1 expression inhibited the migration of SKOV3 cells and reduced colony formation of SKOV3 cells without affecting cell proliferation.[24] These results suggest that KiSS-1 serves as a metastasis suppressor for ovarian cancer. In this study, we evaluated the expression level of *metastin* and *AXOR12* genes in epithelial ovarian cancer, and a good agreement was noted between *metastin* and *AXOR12* gene expression levels (kappa coefficient; 0.74). Moreover, high *AXOR12* gene expression and high expression of both *metastin* and *AXOR12* genes significantly were associated with the improved patient prognosis in this study. Metastin/AXOR12 signalling might suppress the tumour aggressive phenotype in epithelial ovarian cancer. Similar results have been reported in melanoma,[6] thyroid cancer,[7] oesophageal carcinoma,[8] urinary bladder cancer[9] and gastric carcinoma.[10]

More recently, Martin and colleagues[25] noted that KiSS-1 expression is increased in human breast cancer, particularly in patients with aggressive tumours and with mortality. Also, it has been reported that Kiss-1 promotes metastasis in a human breast cancer cell line in an *in vitro* study. These results are in direct contrast to a number of previous studies[6–10] and show that KiSS-1 plays a role beyond the initial metastasis repressor in breast cancer. Ikeguchi and colleagues[26] examined the clinical importance of KiSS-1 and its receptor gene expression in hepatocellular carcinoma. They evaluated 60 surgically resected carcinomas using real-time quantitative RT-PCR and found that there was no loss of KiSS-1 in carcinomas compared to non-cancerous cirrhotic livers. Conversely, they found a high expression of the receptor in



Fig. 4 – Localisation of analysis of *metastin* and a G-protein-coupled receptor (AXOR12) in a section of clear cell carcinoma by *in situ* hybridisation. Metastin (A, original ×400) and AXOR12 (C, original ×400) mRNA-expressing cells are found in the epithelial ovarian carcinoma cells, respectively. In metastin (B, original ×400) and AXOR12 (D, original ×400) sense-control hybridisation, only background colour with no distinction is observed, respectively.

the carcinomas. There was over-expression of KiSS-1 and its receptor in six tumours of advanced stage and those patients had poor survival. These authors concluded that over-expression of KiSS-1 and its receptor was frequently observed and correlated with disease progression.[26] It appears that although KiSS-1 may be a possible metastasis suppressor in melanoma,[6] thyroid cancer,[7] oesophageal carcinoma,[8] urinary bladder cancer,[9] gastric carcinoma,[10] and epithelial ovarian cancer, however, this is not always true as it was found in breast and hepatocellular cancers. Further research is necessary before the true role and effect of Metastin/AXOR12 signalling in each tumour can be elucidated.

KiSS-1 peptides, such as metastin and its receptors were highly expressed in placenta,[4,23] and metastin was isolated from human placental extracts.[4] Metastins were detected in plasma, and their concentrations dramatically increased under certain physiological conditions, such as pregnancy. Histochemical studies detected metastin mRNA in human placenta and immunoreactivity in the syncytiotrophoblasts.[27] These data may indicate that metastin is a novel placenta-derived hormone in humans. There are striking similarities between the behaviour of invasive placental cells and the invasive cancer cells.[28,29] Like tumour cells, cytotrophoblastic cells migrate through and invade the uterine wall at the time of implantation. Unlike tumour invasion, this unique interaction between genetically dissimilar trophoblasts and uterine cells is closely regulated and is limited both temporally and spatially by mechanisms that are largely unknown. Considering the localisation of mRNA for metastin and AXOR12 in syncytiotrophoblasts confirmed in the present study and a dramatic elevation of plasma metastin concentration in the first trimester of pregnancy,[27] it is possible that metastin/AXOR12 signalling may be involved in the negative regulation of trophoblast invasion because unlike the tumour cells trophoblasts never metastasise to distant location. In this study, transcripts for metastin and AXOR12 were detected in the epithelial ovarian carcinoma cells, respectively, by *in situ* hybridisation analysis. Similarly, it might be possible that high expression of both *metastin* and *AXOR12* genes in epithelial ovarian cancer cells, as detected in this study, is responsible for the inhibition of cellular invasion and metastasis; however, this speculation is still putative.

The real-time quantitative RT-PCR method we used for the determination of *metastin* and *AXOR12* gene expressions is convenient because it does not require radioisotopes or relatively large amounts of tumour tissues, and is reliable and accurate. Even biopsy samples could be used for an accurate evaluation of *metastin* and *AXOR12* gene expressions. The

real-time quantitative RT-PCR detection method of these genes might serve as a tool to diagnose the high-risk group of patients with epithelial ovarian cancer who might have worse prognosis. Also the expression pattern of these genes may provide a new insight to understand the biology of epithelial ovarian cancer. Further investigation is necessary in a large number of epithelial ovarian cancer patients before the findings of the present study would be considered for clinical application.

Conflict of interest statement

None declared.

REFERENCES

1. Lee JH, Miele ME, Hicks DJ, et al. Kiss-1, a novel human malignant melanoma metastasis-suppressor gene. *J Natl Cancer Inst* 1996;88:1731–7.
2. Lee JH, Welch DR. Identification of highly expressed genes in metastasis-suppressed chromosome 6/human malignant melanoma hybrid cells using subtractive hybridization and differential display. *Int J Cancer* 1997;71:1035–44.
3. Lee JH, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. *Cancer Res* 1997;57:2384–7.
4. Ohtaki T, Shintani Y, Honda S, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. *Nature* 2001;411:613–7.
5. Hori A, Honda S, Asada M, et al. Metastin suppresses the motility and growth of CHO cells transfected with its receptor. *Biochem Biophys Res Commun* 2001;286:958–63.
6. Shirasaki F, Takata M, Hatta N, Takehara K. Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. *Cancer Res* 2001;61:7422–5.
7. Ringel MD, Hardy E, Bernet VJ, et al. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. *J Clin Endocrinol Metab* 2002;87:2399–402.
8. Ikeguchi M, Yamaguchi K, Kaibara N. Clinical significance of the loss of Kiss-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in esophageal squamous cell carcinoma. *Clin Cancer Res* 2004;10:379–83.
9. Sanchez-Carbayo M, Capodieci P, Cordon-Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. *Am J Pathol* 2003;162:609–17.
10. Dhar DK, Naora H, Kubota H, et al. Downregulation of Kiss-1 expression is responsible for tumour invasion and worse prognosis in gastric carcinoma. *Int J Cancer* 2004;111:868–72.
11. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. *CA Cancer J Clin* 2005;55:10–30.
12. International Federation of Gynecology and Obstetrics (FIGO). Changes in definitions of clinical staging for carcinoma of the cervix and ovary. *Am J Obstet Gynecol* 1987;156:263–4.
13. Hata K, Kamikawa T, Arao S, et al. Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. *Br J Cancer* 1999;79:1848–54.
14. Hata K, Fujiwaki R, Nakayama K, Miyazaki K. Expression of endostatin gene in epithelial ovarian cancer. *Clin Cancer Res* 2001;7:2405–9.
15. Serov SF, Scully RE, Sobin LH. *International histological classification of tumours, no. 9: histological typing of ovarian tumours*. Geneva: World Health Organization; 1973.
16. Arao S, Suwa H, Mandai M, et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. *Cancer Res* 1994;54:1355–9.
17. Hata K, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Miyazaki K. Expression of the angiopoietin-1, angiopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. *Gynecol Oncol* 2004;93:215–22.
18. Nagasue N, Dhar DK, Yamanoi A, et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. *Hepatology* 2000;31:1107–14.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159–74.
20. Preston DL, Lubin JH, Pierce DA. *EPICURE: risk regression and data analysis software*. Seattle: HiroSoft International Corporation; 1990.
21. Beale PJ, Friedlander ML. Prognostic variables in ovarian cancer. In: Lawton FG, Neijt JP, Swenerton KD, editors. *Epithelial cancer of the ovary*. London: BMJ Publishing Group; 1995. p. 96–111.
22. Harms JF, Welch DR, Miele ME. KISS1 metastasis suppression and emergent pathways. *Clin Exp Metast* 2003;20:11–8.
23. Muir AI, Chamberlain L, Elshourbagy NA, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. *J Biol Chem* 2001;276:28969–75.
24. Jiang Y, Berk M, Singh LS, et al. KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. *Clin Exp Metast* 2005;22:369–76.
25. Martin TA, Watkins G, Jiang WG. KiSS-1 expression in human breast cancer. *Clin Exp Metast* 2005;22:503–11.
26. Ikeguchi M, Hirooka Y, Kaibara N. Quantitative reverse transcriptase polymerase chain reaction analysis for KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in hepatocelluar carcinoma. *J Cancer Res Clin Oncol* 2003;129:531–5.
27. Horikoshi Y, Matsumoto H, Takatsu Y, et al. Dramatic elevation of plasma metastin concentrations in human pregnancy: metastin as a novel placenta-derived hormone in humans. *J Clin Endocrinol Metab* 2003;88:914–9.
28. Murray MJ, Lessey BA. Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis. *Semin Reprod Endocrinol* 1999;17:275–90.
29. Bischof P, Meisser A, Campana A. Paracrine and autocrine regulators of trophoblast invasion – a review. *Placenta* 2000;21:S55–60.

Available online at www.sciencedirect.com
ScienceDirect
Cancer Letters 251 (2007) 164–167
CANCER Letters
www.elsevier.com/locate/canlet

Hypoxia inducible factor 1-α expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer

Hidekatsu Nakai, Yoh Watanabe *, Haruhiko Ueda, Hiroshi Hoshiai

Department of Obstetrics and Gynecology, Kinki University School of Medicine, 377-2 Ohno-Higashi Osakasayama, Osaka 5898511, Japan

Received 12 September 2006; received in revised form 18 October 2006; accepted 16 November 2006

Abstract

To investigate the impact on survival of HIF 1-α expression on primary advanced epithelial ovarian cancer (EOC), we examined the correlations between prognosis and HIF 1-α expression by Western blot analysis in 52 cases of stage III/IV EOC. HIF 1-α expression was confirmed in 36 cases (69.2%) of EOC, and HIF 1-α-expressing tumors had a significantly higher rate of response ($p < 0.01$) to postoperative paclitaxel/carboplatin combination chemotherapy (TC) than tumors without HIF1-α expression. Moreover, patients with HIF 1-α-expressing tumors with suboptimal resection of stage III/IV tumors indicated for postoperative TC exhibited significantly better survival ($p < 0.01$).

Keywords: HIF 1-α; Epithelial ovarian cancer; Chemotherapy; Prognostic factor

1. Introduction

Hypoxia inducible factor 1-α (HIF 1-α) has been reported to be an important predictor of tumor progression for several types of solid cancers [1–5]. However, although several *in vitro* studies have reported correlations between HIF 1-α expression and cell biological features in ovarian cancer, study of the clinical significance of HIF 1-α still has been limited [6]. To determine the clinical usefulness of HIF 1-α expression in treatment of primary epithelial ovarian cancer (EOC), we examined whether HIF 1-α expression can predict effects of postoperative induction chemotherapy and long-term prognosis in patients with stage III/IV advanced EOC.

2. Materials and methods

The study included 52 cases of stage III/IV EOC. Fourteen patients underwent optimal resection (residual tumor <1 cm), while 38 patients underwent suboptimal resection at primary surgery. Furthermore, all patients with suboptimal resection had measurable disease usable for determining direct effects of TC. The clinicopathological characteristics of patients did not differ significantly between optimal resection and suboptimal resection as summarized in Table 1. All of the patients were indicated for postoperative TC (175–180 mg/m^2 paclitaxel and a dose of carboplatin an area under the concentration curve

* Corresponding author. Tel.: +81 72366 0221; fax: +81 72368 3745.
E-mail address: watanabe@med.kindai.ac.jp (Y. Watanabe).

0304-3835/$ - see front matter © 2006 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.canlet.2006.11.017

Table 1
Correlations between HIF-1 α expression and clinicopathologic factors

Factors	HIF-1 α[a] positive	HIF-1 α negative
Total number of cases	36	16
Mean ages (range)	57.9 ± 8.2 years (34–84)	57.2 ± 7.3 years (39–73)
FIGO stage (%)[b]		
Stage III	31 (68.9)	14 (31.1)
Stage IV	5 (71.4)	2 (28.6)
Histologic subtype (%)		
Serous	19 (65.5)	10 (34.5)
Endometrioid	7 (77.8)	2 (22.2)
Mucinous	3 (60.0)	2 (40.0)
Clear-cell	7 (77.8)	2 (22.2)
Histologic grade (%)[c]		
Grade 1	13 (68.4)	6 (31.6)
Grade 2	10 (71.4)	4 (28.6)
Grade 3	6 (60.0)	4 (40.0)
Surgical status (%)		
Optimal surgery	9 (64.3)	5 (35.7)
Sub optimal surgery	27 (77.1)	11 (28.9)
Overall response rate of postoperative chemotherapy (%)	18 (66.7)	5 (45.5)**
Complete response rate of postoperative chemotherapy (%)	13 (48.1)	2 (18.2)**

[a] HIF, hypoxia inducible factor.
[b] FIGO, Federation of International Gynecology and Obstetrics.
[c] Not including clear-cell carcinomas.
** $p < 0.01$.

by Calvert's formula of 5–6). Direct effects of chemotherapy were assessed using the World Health Organization criteria. HIF 1-α expression was determined by Western blot analysis using anti-HIF 1-α (Novus Biologicals, Littleton, CO) for stocked fresh-frozen tissues, and if an independent positive band in the region of 120 kDa was confirmed on quantification using NIH image analysis, it was taken to indicate HIF 1-α expression (Fig. 1). We obtained fully informed written consent from all patients prior to obtaining the specimens. We used the chi-square test and log-rank test for statistical analysis, with p-values less than 0.05 considered significant.

3. Results

HIF 1-α expression was confirmed in 36 (69.2%) of the patients with FIGO stage III/IV tumors, and no significant correlation was observed between frequency of HIF 1-α expression and patient age, histologic subtype, histologic grade, FIGO stage (III or IV), or surgical status (optimal or suboptimal resection). However, HIF 1-α-expressing tumors exhibited significantly higher overall response rate ($p < 0.01$) and complete response rate ($p < 0.01$) to TC than tumors without HIF 1-α expression (Table 1). Moreover, HIF 1-α predicted prognosis for neither the group of all stage III/IV patients nor that with optimal resection. Although no significant differences were noted in clinicopathologic characteristics between patients with optimal and those with suboptimal resection (Table 2), but among patients in stage III/IV who underwent suboptimal resection at primary surgery and were indicated for postoperative TC, those with HIF 1-α-expressing tumors had a significantly better prognosis than those with tumors without HIF 1-α expression (Fig. 2).

4. Discussion

HIF 1-α expression in malignant tumors has been reported as a predictive factor for tumor progression and a prognostic factor correlated with angiogenesis. However, HIF 1-α expression in solid cancers exhibits marked variation among primary organs in the English literature [1–5]. Generally, HIF 1-α predicts tumor progression, and HIF 1-α-



Fig. 1. The expression of HIF 1-α proteins detected by Western blotting. Lane 1: positive control; HCT-116 cell were grown in a chamber containing 1% oxygen, 5% carbon dioxide, and 94% nitrogen at 37 degree for 3 days. Lane 2: negative control; without primary antibody. Lane 3 and 4: HIF 1-α positive cases. Lane 5: HIF 1-α negative case.

Table 2
Clinicopathologic characteristics of all patients

Factors	Optimal	Suboptimal
Total number of cases	14	38
Mean ages (range)	59.6 + 8.3 years (46–84)	57.1 ± 7.6 years (34–74)
FIGO stage (%)[a]		
Stage III	13 (92.8)	32 (84.2)
Stage IV	1 (7.2)	6 (15.8)
Histologic subtype (%)		
Serous	9 (64.3)	20 (52.6)
Endometrioid	2 (14.3)	7 (18.4)
Mucinous	1 (7.1)	4 (10.6)
Clear-cell	2 (14.3)	7 (18.4)
Histologic grade (%)[b]		
Grade 1	6 (50.0)	13 (41.9)
Grade 2	4 (33.3)	10 (32.3)
Grade 3	2 (16.7)	8 (25.8)
Mean treatment courses (range)	5.9 ± 0.3 course (4–6)	5.8 ± 0.9 courses (3–6)
Mean follow up period (range)	58.4 ± 31.4 months (13–135)	48.3 ± 26.3 months (8–110)

[a] FIGO, Federation of International Gynecology and Obstetrics.
[b] Not including clear-cell carcinomas.

expressing cancers tend to have a poor prognosis. However, Nakayama et al. [6] reported finding no relationship between HIF 1-α expression and intratumoral microvessel density, and that vascular endothelial cell growth factor (VEGF) up-regulated HIF 1-α gene, though levels of expression of neither gene affected the survival of patients with EOC. Furthermore, Birner et al. [7] examined HIF 1-α expression in 102 cases of FIGO stage I–IV EOC by immunohistochemical staining, reported that 68.6% of cases of EOC expressed HIF 1-α, and concluded that HIF 1-α protein overexpression also has no impact on prognosis and that response to TC is independent of HIF 1-α expression. However, Escuin et al. [8] recently found that microtubule-targeting drugs, such as taxanes, could be effective in down-regulating HIF 1-α protein via effects on microtubule cytoskeleton that are correlated with HIF 1-α translation activity. For patients with suboptimally resected advanced EOC, survival impact is closely related to effects of postoperative chemotherapy. Therefore, because paclitaxel may exhibit anti-angiogenetic effects through down-regulation of HIF 1-α protein expression, the survival impact of HIF 1-α expression on EOC may be noted only in patients who are stage III/IV, have undergone



Fig. 2. Correlation between survival and HIF 1-α expression in stage III/IV epithelial ovarian cancer. (A) Progression-free survival in the group of all stage III/IV patients. (B) Progression-free survival of stage III/IV patients who underwent optimal resection at primary surgery and were indicated for postoperative paclitaxel/carboplatin chemotherapy. (C) Progression-free survival of stage III/IV patients who underwent suboptimal resection at primary surgery and were indicated for postoperative paclitaxel/carboplatin chemotherapy. *p*-values were calculated with the log-rank test.

suboptimal resection at primary surgery, and are indicated for postoperative TC. Although TC has been widely used as an effective standard regimen of chemotherapy for primary or recurrent EOC, and TC has achieved a 65–75% overall response rate in several phase 3 clinical trials [9,10], no factors predictive of TC have been found. The present findings suggest that although expression of HIF 1-α is not a factor predictive of survival of patients with early-stage or optimally resected advanced EOC, it does predict the efficacy of chemotherapy using TC. Furthermore, determination of HIF 1-α expression should be useful for devising individualized treatment regimens for advanced EOC. Clinical trials targeting HIF 1-α treatment using taxanes are needed to improve the long-term prognosis of patients with suboptimally resected advanced EOC.

References

[1] G. Gruber, R.H. Greiner, R. Hlushchuk, D.M. Aebersold, H.J. Altermatt, G. Berclaz, V. Djonov, Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?, Breast Cancer Res 6 (2004) 191–198.

[2] T. Kurokawa, M. Miyamoto, K. Kato, Y. Cho, Y. Kawarada, Y. Hida, T. Shinohara, T. Itoh, S. Okushiba, S. Kondo, H. Katoh, Overexpression of hypoxia-inducible-factor 1 alpha (HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage, Br. J. Cancer 89 (2003) 1042–1047.

[3] A. Lidgren, Y. Hedberg, K. Grankvist, T. Rasmuson, J. Vasko, B. Ljungberg, The expression of hypoxia-inducible factor 1 alpha is a favorable independent prognostic factor in renal cell carcinoma, Clin. Cancer Res. 11 (2005) 1129–1135.

[4] D.E. Swinson, J.L. Jones, G. Cox, D. Richardson, A.L. Harris, K.J. O'Byrne, Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathway, Int. J. Cancer 111 (2004) 43–50.

[5] T. Fillies, R. Werkmeister, P.J. Van Diest, B. Brandt, U. Joos, H. Buerger, HIF 1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor, BMC Cancer 5 (2005) 84.

[6] K. Nakayama, A. Kanzaki, K. Hata, H. Katabuchi, H. Okamura, K. Miyazaki, M. Fukumoto, Y. Takebayashi, Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma, Cancer Lett. 176 (2002) 215–223.

[7] P. Birner, M. Schindle, A. Obermair, G. Breitenecker, G. Ober huber, Expression of hypoxia-inducible factor 1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy, Clin. Cancer Res. 7 (2001) 1661–1668.

[8] D. Escuin, E.R. Kline, P. Giannakakou, Both microtubule-stabilizing and micro tubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function, Cancer Res. 65 (2005) 9021–9028.

[9] A. du Bios, H.J. Luck, W. Meier, V. Mobus, S. Costa, B. Richter, M. Warm, T. Bauknecht, W. Schroder, S. Olbricht, U. Nitz, C. Jackisch. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer; an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie, Ovarian Cancer Study Group. Semin Oncol. 24 (1997) S15-44–52.

[10] P.A. Vasey, G.C. Jayson, A. Gordon, H. Gabra, R. Coleman, R. Atkinson, D. Parkin, Paul randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line J, A. Hay, S.B. Kaye. Scottish Gynaecological Cancer Trials Group, Phase III chemotherapy for ovarian carcinoma, J. Natl. Cancer Inst. 96 (2004) 1682–1691.

Current Organ Topics:

Gynecologic Cancer
婦人科 癌

Ⅲ．子宮体癌における化学療法

寒河江 悟，杉村 政樹（札幌鉄道病院産婦人科）

〔*Jpn J Cancer Chemother* 35(2): 218-223, *February*, 2008〕

はじめに

2006年11月28, 29日英国のマンチェスターにて子宮体癌に関する国際会議が開催され，分子メカニズム，治療法，今後の臨床試験のあり方について，早期がん，進行がん，稀な組織型（明細胞，漿液性腺癌など）の治療，translational research などを対象に討議された[1]。これは英国の NCRI，米国の NCI-US，さらに国際的臨床試験グループである GCIG の共同開催であり，その内容から現在世界の専門家はどのような理解のもとに今後の臨床研究を考えているのかを整理し，特に化学療法に焦点を当てて解説してみたい。

1．原則は手術療法

子宮体癌の治療は，あくまで手術療法の役割が中心である。そこで術後の再発危険因子を理解することが最も重要であり，子宮体癌の術後管理をいかに正確に行うかに直結する課題である。再発危険因子は子宮内因子と子宮外因子に分けられ[2]，表1のごとく多くの因子が存在し，それぞれが FIGO の進行期分類で反映されている[3]。

表1 子宮体癌の予後因子

Uterine Factors	Extrauterine Factors
Histology	Adnexal Metastases
Grade	Intraperitoneal Spread
Myometrial Invasion	Peritoneal Cytology
Cervical-Isthmus Extension	Pelvic Node Metastases
Lymph-Vascular Invasion	Paraortic Node Metastases

昨今はこれらの危険因子を危険度の程度別に，low, intermediate, high risk などとグループ分けされ詳細に検討されている（図1）。そしてこれらが種々の治療法の選択に欠かせない指針となっている。従って，正確な術後進行期の決定がその症例の予後を語るもっとも正確な手段であることは議論の余地がない。

こと手術に関しては，単純子宮全摘術とは異なり，広汎子宮全摘術を子宮体癌で行うことが骨盤内や膣断端への再発を減らすとされ，リンパ節への再発転移をも低くするものとされてきたが，早期であるⅠ期症例への広汎子宮全摘術を支持する証拠は何もない。この手術は明らかな頸管浸潤を伴ったⅡb期症例に限られるべきである[4]。リンパ節郭清の効用は疾患の進行期を決め，そうすることで予後を推測し術後療法の必要性を決めることである。しかしリンパ節を摘出すること自体が治療的意義があるか否かは今日もっとも議論のあるところである[5]。2007年米国での ASCO 総会にて ASTEC 試験の報告[6]があり，二段階の無作為化試験により TAH & BSO 後にリンパ節郭清を行うかどうかと，病理学的に再発高危険群であるが肉眼的に完全に摘出された症例には，放射線の外照射を行うか否かにより，生存期間が比較された（図2）。全生存期間は治療法で差はなかったが，無再発期間はリンパ節郭清のない群で，行った群より優っていた。彼らは多数の症例での成績であり骨盤リンパ節郭清は特に術後療法の存在下では生存期間を延長するものではないと結論した。リンパ節郭清群には無再



図1 リスク別術後療法のシェーマ



図2 ASTEC 臨床試験 ASCO2007

表 2 Radiotherapy versus Chemotherapy in endometrial cancers JGOG2033[11], Italian Study[12] and GOG122[13]

	JGOG2033* (Susumu N, 2007)	Italian Study (Maggi R, 2006)	GOG 122 (Randall ME, 2006)
Regimen RT	Pelvic	Pelvic±PA	WAI
CT	CAP	CAP	AP
Number of Patients	385	340	396
Disease Stage	Ⅰc, 61%; Ⅱ, 14% Ⅲ, 25%	Ⅰ, 26.5%; Ⅱ, 9% Ⅲ, 64.5%	Ⅲ, 73%; Ⅳ, 27%
5-year PFS RT	84	63	38
CT	82	63	50**
5-year OS RT	86	69	42
CT	87	66	55**

*In press **Adjusted for stage, $p<0.01$

発期間の短い傾向が確認され，さらに術後の放射線治療によるリンパ浮腫の増大という危険性もあると強調した。日本の婦人科がん化学療法研究機構 JGOG は子宮体癌に関するアンケート調査[7]を行い，子宮の摘出方法やリンパ節郭清には国内的に種々の方法が用いられていることを報告し，子宮摘出法は単純と Piver Ⅱ型（いわゆる準広汎）が1/3ずつで，あとは進行期を考慮して子宮を摘出するというものであった。さらなる広汎手術を行うか否かの質問では，30%のみが行うと回答し，決して子宮を広範囲に摘出することが予後改善につながるとは考えていない。また傍大動脈リンパ節郭清については，いつも行うのが13%しかなく，81%は腫瘍関連因子の存在で選択的に行っていたし，6%の施設では全然行っていなかった。この場合の腫瘍関連因子は傍大動脈リンパ節転移，分化度3，筋層浸潤1/2以上，組織型が漿液性・明細胞，骨盤リンパ節転移などが20%以上の因子であった。結論としては子宮体癌の手術術式はいまだ標準化されておらず，子宮全摘術，両側付属器摘出術，骨盤リンパ節郭清，選択的傍大動脈リンパ節郭清が日本で行われている子宮体癌の今日的術式であることが判明した。子宮体癌における手術に関する三大問題点は，子宮の摘出術式すなわち単純か広汎か，リンパ節郭清か生検か，傍大動脈リンパ節の扱いである。これらの種々の術式の治療的意義を決定づける臨床試験を大々的に行うことは，子宮体癌における術式の標準化に最も寄与するであろうと結論つけられた。

2．術後療法

次に骨盤放射線療法，すなわち外照射と腔内照射は，これまで何十年も広く子宮体癌治療の基本であった。特に進行期不明な症例の術後療法の場合や intermediate や high リスク症例やリンパ節転移症例など，さらに摘出不能な骨盤内進展症例などには放射線療法が標準であった。Intermediate リスク症例に対する放射線療法は三つの無作為化臨床試験が存在し，the Norwegian trial[8]，PORTEC Ⅰ[9]，GOG99[10]である。これらはすべて骨盤内再発の減少には寄与するが，最終生存には寄与しなかった。さらに GOG 試験ではリンパ節郭清後の骨盤照射群に合併症の明らかな増加を認めた。

術後療法としての放射線療法と化学療法を直接比較した日本の臨床試験は2005年に ASCO で報告されたが，Ⅰc期からⅢ期までの385例が登録され，CAP 療法と骨盤放射線療法が比較された[11]が，これまでに放射線療法と化学療法の直接比較は三つの臨床試験（表2）しか存在せず，JGOG2033[11]，Italian Study[12]，GOG122[13]である。これらを比較すると，JGOG2033 では完全手術で筋層浸潤1/2以上症例でⅠcからⅢc期まで登録され，類内膜腺癌385例が放射線療法と CAP 化学療法の無作為化比較試験で検討された。一次評価項目は全生存期間であり，二次的には無再発期間と副作用であった。両群は年齢，閉経，合併症，術式，進行期などに有意な差はなく，Ⅰc期61%，Ⅱ期14%，Ⅲa期13%，Ⅲc期12%であった。約74%がⅠcからⅡb期までであった。結論としては385例での両群の比較では無再発や全生存期間には全く差はなく，サブ解析で intermediate リスクでもさらに再発危険度の低い群190例では両群に予後の差はないが再発危険度の高い群（Ⅱ期からⅢa期など）では放射線治療群より有意に化学療法群で予後良好であった[11]。

Italian Study の high リスク子宮体癌症例に対する放射線療法と化学療法 CAP 療法の比較であり，Ⅰc/Ⅱ期 G3 とⅢ期症例345例が登録され，化学療法は cisplatin (CDDP) 50 mg/m^2，doxorubicin (DXR) 45 mg/m^2，cyclophosphamide (CPA) 600 mg/m^{2}を4週毎に5サイクルであり，放射線療法は外照射（45～50 Gy 週5日治療）であった。両群で全生存期間に差はなかったが放射線療法は骨盤内再発を遅らせ，化学療法は遠隔転移を遅らせた[12]。



図 3 GOG209[15]



図 4 Ongoing Phase Ⅲ JGOG2043[18]

進行子宮体癌での放射線療法と化学療法の比較はGOG122研究があり2004年にASCOで報告され2006年に論文化された。全腹腔内照射とAP化学療法の比較であり，396例のⅢ期Ⅳ期症例が登録され，予後の比較では神経障害や心毒性がより強く出たが，明らかに放射線療法より化学療法が良好であった。この研究結果はその後の治療法に多大なインパクトを与え，標準であった放射線療法から選択肢としての「化学療法」の時代へのあけぼののようであった[13]。

3．子宮体癌における化学療法

それまでの化学療法は進行・再発子宮体癌症例の中でも肥満症例や前回放射線療法症例，高齢者などに限られていた。化学療法の既往なし症例では20%程度の効果が期待できた。たとえばDXR/epirubicin（EPI），paclitaxel（PTX）/docetaxel（DOC），さらにCDDP/carboplatin（CBDCA）などの併用療法である。AP療法は長い間唯一の標準化学療法であったが，GOGがAP対AP+PTX（TAP）の比較試験GOG177を行った[14]。既往の化学療法なしで測定可能病変がある進行・再発子宮体癌症例を対象に，AP療法とAP+PTX（G-CSF補助）療法の比較を行った。結果としてTAP療法が生存率の優越性を認めたが副作用が重症であり死亡症例も認められた。そこで現在より副作用の少ないPTX/CBDCA療法が第Ⅱ相試験で検討され60%を越える奏効率が得られている。そこで現在GOGではTAP療法vsTC療法の比較をⅡ期からⅣ期子宮体癌症例を対象に登録を進めている（GOG209）（図3）。本試験にはJGOGの中のGOG Japanを通じて日本人女性も登録が行われており，今後の研究成果が期待されている。

これらの状況の中，JGOGは最近さらに子宮体癌における化学療法のアンケート調査を行い，国内的にもPTX/Platinum（CBDCA）が最も汎用されている化学療法であることが示されている[15]。JGOGでは数年前からTaxane系薬剤とプラチナ系薬剤の併用の中で最も有効な薬剤の検討も始めており，JGOG2041では，DOC/CDDP，DOC/CBDCA，PTX/CBDCAの3種類の併用療法を30例ずつ登録し，2004年に登録終了し現在予後解析を待っているところである。中間解析ではPTX/CDDPが最も神経毒性が強かった[16]。3併用療法の中で副作用の出現頻度は異なり，DOC/CDDPでは消化器毒性がより強く発現し，DOC/CBDCAやPTX/CBDCAでは貧血や血小板減少がより高頻度であった。さらに1年経過での奏効率はDOC/CDDPで51.7%であり，PTX/CBDCAは60.0%であったが，DOC/CBDCAでは48.3%とやや低かった。

このJGOG2041に引き続き，現在国内では臨床第Ⅲ相試験JGOG2043（図4）が進行中である[17]。Ⅰc期，G2/G3，Ⅱ/Ⅲ期子宮体癌の術後治療として3種類の併用化学療法が無作為化され，登録が進んでいる。化学療法の内容はJGOG2041で評価されたDOC/CDDPとPTX/CBDCAであり，対照治療がこれまでの基本であるAP療法の3治療法である。現在各群200例の目標に対しやや登録が遅れているがすでに計100例以上の登録がなされており，今後の登録を期待しつつ最終成績に注目しているところである。一次評価項目は無再発期間であり，二次評価項目は全生存期間，副作用，治療内容，リンパ節転移などである。本研究は，GOG209と並んで，子宮体癌に対するTaxane系薬剤とプラチナ系薬剤の併用療法のなかで何が最も効果的なのかを決定することにもなり極めて重要である。

4．ホルモン療法

ホルモン療法は過去40年以上にわたって進行・再発子宮体癌症例に効果があるとされてきた。単剤プロゲステロン製剤（GOG48やGOG81[18]）ではPR陽性腫瘍やG1腫瘍に20%の奏効率があるとされた。またプロゲステロン製剤とタモキシフェンの併用療法（GOG119 and GOG153[19]）は30%内外の臨床効果があるとされた。さらに昨今ではaromatase inhibitors，anastrozoleやle-

trozoleなどの臨床効果が検討されたが極めて限定的であった。またホルモン剤のこれまでの臨床試験を総合的に判定したMeta-analysisでは，プロゲステロン製剤は初回治療の補助療法としての臨床効果は有効でないと結論されている[20]。それでも子宮体癌症例に対する保存的治療法への応用も本邦では検討され，早期子宮体癌や内膜増殖症の症例にMPAを投与する第Ⅱ相試験がこのほど発表された[21]。40歳未満のⅠa期子宮体癌症例28例と異型内膜増殖症17例の合計45例が登録され，MPA 600 mgを低用量アスピリンとともに26週間連続投与された。病理学的CRは子宮体癌症例の55%，異型増殖症の82%で観察され，全体でpCR率は67%にのぼった。これらの症例群では経過観察3年間で12例にその後妊娠が確認され，7例で無事出産にこぎつけている。従って子宮体癌や異型増殖症に対する妊孕能温存高用量MPA療法の有用性はこの前方視的研究により証明された。しかし有効例においても実質的再発率の高さから厳重な経過観察が必要であることが結論つけられた。

5．分子標的療法

現在，生物学的治療法が種々の分子標的に対して多くの臨床試験が実施されている。子宮体癌においても同様であり，大きな流れとして二つの方向性が現存する。すなわちひとつは子宮体癌で43%に発現しているPTENに対する治療法である。PTEN機能の欠損がAKTを増加させ，mTORを増加させる。原発腫瘍ではmTORが70%で増加しており，再発腫瘍でも50%で増加しており，このmTOR抑制剤は治療に極めて重要である，たとえばRAD001[22]，CCI-779（NCIC）などが報告されており，CCI-779は16例中5例のPRが得られ31%の奏効率を報告している[23]。もうひとつはEGFRに対する治療法である。EGFRは子宮体癌の60～80%（とくに漿液性）に発現しており，EGFR標的治療はこれまで多くの薬剤が開発され，たとえばIressa（GOG 229-C），Herceptin（GOG 181b），and Erlotinibなどであり，OSI-774（NCIC）では7%の奏効率が報告されている。

6．ASCO2007におけるNSGO/EORTC臨床試験

以上のごとく，子宮体癌に対する化学療法にも種々の薬剤の試みが現在進行中である。そのような状況の中，本年のASCOで子宮体癌の治療法に関して極めて重要な報告がなされた。それはNSGO/EORTCの共同研究であり，早期highリスク子宮体癌症例の術後療法として，放射線単独療法か，それに化学療法を併用するか否かの無作為化臨床試験（図5）である[24]。登録の基準は，子宮全摘術と両側付属器摘出術の後に手術進行期Ⅰ期とⅡ期，さらに腹腔内細胞診陽性のⅢa期，骨盤リンパ節転移要請のⅢc期を対象にしており，さらに漿液性，明細胞，未分化癌などは他のリスク因子の有無にかかわらず登録対象としている。症例は放射線療法群と放射線療法と化学療法の併用群に無作為に分けられ，化学療法はこれまで有効とされたAP，TP，TAP，またはTEP療法などが含まれている。一次評価項目は無再発期間であり，90%の症例が進行期Ⅰ期に属したが，67%は類内膜腺癌G3，明細胞，漿液性がんであった。これまでの試験の結果は無再発期間で両群間に明らかに差があり，放射線療法に化学療法が併用された群で有意に予後良好であった。演者らはこれらのデータより，併用群に割り振られた症例の27%が化学療法を受けなかったり，一部しか受けなかったにもかかわらず，両治療法の併用が早期子宮体癌で微小転移を認めるhighリスクの症例には術後療法として両治療法の併用が放射線療法単独より有用であると結論した。NSGO/EORTCでは現在今後の臨床試験としてまずは術後に化学療法を行い，その後に放射線療法を行うか否かの臨床試験を企画中である。ということは，NSGO/EORTCでは早期子宮体癌の術後療法の標準は化学療法であり，高intermediateリスク症例である微小転移を認める可能性がある症例がまさに適応であると伝えている。



図5　NSGO and EORTC at ASCO 2007.[31]

最後に，2006年英国で開催された子宮体癌に関するコンセンサス国際会議のまとめとして，

A）今後早期子宮体癌に対する術後療法としては化学療法の重要性を十分に認識しておかなければならない。今後将来の方向性として注目される臨床試験は以下のごとくである。

1）現在登録中のPORTEC Ⅲ臨床試験

これは骨盤放射線療法と化学療法併用放射線療法＋地固め化学療法の比較である。対象はⅠb期Ⅰc期G3，Ⅱ期G3，Ⅲa期またはⅡc期の類内膜腺癌，さらにⅠb期からⅢc期までの明細胞か漿液性癌である。化学療法併用放射線療法は7日目と22日目にCDDP 50 mg/m^{2}を併用し，地固めにPTX/CBDCA（175/AUC5）を3週毎

に4サイクル行うものである。800例の登録を予定している。

2）骨盤放射線療法と化学療法＋腔内照射の比較をリンパ節転移陰性の子宮体癌に行う無作為化比較試験

3）手術進行期を決定してリンパ節転移があった症例に化学療法を追加する群と手術なしに骨盤照射と化学療法の併用を行う群の無作為化比較試験

B）さらに進行子宮体癌への治療としてⅢ期症例の術後地固め療法として，NSGO/EORTCの今回の発表の延長として全身化学療法に放射線療法の有無による無作為化比較試験も期待される。

C）そして最後に再発子宮体癌症例に対する治療としては，孤立性の骨盤内再発にはGOG238すなわち放射線療法単独かCDDP併用放射線療法の比較試験が現在進行中である。さらにⅣ期または再発子宮体癌の治療としてPTXはGOG209，TAP vs TCにおいて標準治療の一部として汎用されているし，欧州でのAPとCBDCA/Doxil（liposomal DXR）の比較試験も進行中である。さらには分子標的薬剤CCI-779に化学療法やホルモン療法を併用する臨床試験がGCIGを中心に展開されている。

以上が今後期待される臨床試験としてまとめられた。

文　献

1) Kitchener HC, Trimble EL on behalf of the Endometrial Cancer Consensus Group. Endometrial Cancer State of The Science (SOTS) meeting, sponsored by NCRI, UK, NCI-US, and GCIG.. November 28 and 29th, 2006 Manchester, UK.
2) 日本婦人科腫瘍学会/編: 子宮体癌治療ガイドライン. 2006年版，金原出版，東京，2006.
3) 日本産科婦人科学会・日本病理学会・日本医学放射線学会/編: 子宮体癌取扱い規約. 改定第2版，金原出版，東京，1996.
4) Mariani A, Webb M, Keeney GL, *et al*: Role of wide/radical hysterectomy and pelvic node dissection in endometrial cancer with cervical involvement. *Gynecol Oncol* **83**: 72-80, 2001.
5) Chan JK, Urban R, Cheung MK, *et al*: Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. *Cancer* **109**: 2454-2460, 2007.
6) Orton J, Blake P, *et al*: Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: Results of the randomised MRC ASTEC and NCIC CTG EN. 5 trial. *J Clin Oncol* **25**: 275s (suppl; abstr 5504), 2007.
7) Watanabe Y, Aoki D, Kitagawa R, *et al*: Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey. *Gynecol Oncol* **105**: 325-328, 2007.
8) Aalders J, Abeler V, Kolstad P, *et al*: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients. *Obstet Gynecol* **56**: 419-427, 1980.
9) Creutzberg CL, van Putten WL, Koper PC, *et al*: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial—PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. *Lancet* **355**: 1404-1411, 2000.
10) Keys HM, Roberts JA, Brunetto VL, *et al*: A phase Ⅲ trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* **92**: 744-751, 2004.
11) Susumu N, Sagae S, Udagawa Y, *et al*: Randomized phase Ⅲ trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-risk endometrial cancer: A Japan Gynecologic Oncology Group Study. *Gynecol Oncol* (in press)
12) Maggi R, Lissoni A, Spina F, *et al*: Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial. *Br J Cancer* **95**: 266-271, 2006.
13) Randall ME, Filiaci VL, Muss H, *et al*: Randomized phase Ⅲ trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. *J Clin Oncol* **24**: 36-44, 2006.
14) Fleming GF, Brunetto VL, Cella D, *et al*: Phase Ⅲ trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. *J Clin Oncol* **22**: 2159-2166, 2004.
15) 喜多川亮: オープンデイスカッション子宮体がん委員会 JGOG2044報告．第5回婦人科悪性腫瘍化学療法研究機構総会記録集: 85-87，2007.
16) 青木大輔: オープンデイスカッション子宮体がん委員会 進行・再発子宮体癌に対するDP (Docetaxel＋Cisplatin)，DJ (Docetaxel＋Carboplatin)，TJ (Paclitaxel＋Carboplatin) のランダム化第Ⅱ相試験．第5回婦人科悪性腫瘍化学療法研究機構総会記録集: 74-76，2007.
17) 青木大輔: 子宮体がん再発高危険群に対するAP (Doxorubicin＋Cisplatin) 療法とDP (Docetaxel＋Cisplatin) 療法，TC (Paclitaxel＋Carboplatin) 療法による術後化学療法のランダム化第Ⅲ相試験　JGOG2043.
18) Thigpen JT, Brady MF, Alvarez RD, *et al*: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. *J Clin Oncol* **17**: 1736-1744, 1999.
19) Fiorica JV, Brunetto VL, Hanjani P, *et al*: Phase Ⅱ trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A GOG study. *Gynecol Oncol* **92**: 10-14, 2004.
20) Martin-Hirsch PL, Jarvis G, Kitchener H, *et al*: Progestagens for endometrial cancer. Cochrane Database Syst Rev: CD001040, 2000.
21) Ushijima K, Yahata H, Yoshikawa H, *et al*: Multicenter phase Ⅱ study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J Clin Oncol* **25**: 2798-2803, 2007.
22) Slomovitz BM, Burke T, Lu KH, *et al*: Loss of PTEN expression associated with response to RAD001 (mTOR inhibitor) in patients with recurred endometrial cancer: Translational evaluation from a phase Ⅱ study. *Gynecol Oncol* **104**: S30, (suppl, abstr 70) 2007.
23) Oza Md AM, Elit L, Biagi J, *et al*: Molecular correlates associated with a phase Ⅱ study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer: NCIC IND 160. *J Clin Oncol* **24**: 121s, (suppl; abstr 3003) 2006.
24) Hogberg T, Rosenberg P, Kristensen G, *et al*: A random-